Chiasma (NASDAQ: CHMA) is one of 45 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Chiasma to related companies based on the strength of its profitability, analyst recommendations, dividends, risk, earnings, institutional ownership and valuation.

Insider and Institutional Ownership

50.4% of Chiasma shares are owned by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 3.8% of Chiasma shares are owned by insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Chiasma has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Chiasma’s peers have a beta of 1.28, suggesting that their average share price is 28% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Chiasma and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chiasma 1 0 0 0 1.00
Chiasma Competitors 121 760 1625 59 2.63

As a group, “Biopharmaceuticals” companies have a potential upside of 8.45%. Given Chiasma’s peers stronger consensus rating and higher probable upside, analysts clearly believe Chiasma has less favorable growth aspects than its peers.

Profitability

This table compares Chiasma and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Chiasma N/A -35.96% -31.97%
Chiasma Competitors -12,929.05% 94.48% -18.02%

Valuation & Earnings

This table compares Chiasma and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Chiasma N/A -$29.42 million -1.97
Chiasma Competitors $579.41 million $241.76 million -6.51

Chiasma’s peers have higher revenue and earnings than Chiasma. Chiasma is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Chiasma peers beat Chiasma on 9 of the 12 factors compared.

Chiasma Company Profile

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company’s TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.

Receive News & Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.